Section Arrow
RYTM.NASDAQ
- Rhythm Pharmaceuticals
Quotes are at least 15-min delayed:2025/04/13 01:46 EDT
Last
 59.55
+1.72 (+2.97%)
Day High 
60.12 
Prev. Close
57.83 
1-M High
63.11 
Volume 
681.86K 
Bid
47.6
Ask
60
Day Low
56.115 
Open
57.77 
1-M Low
45.905 
Market Cap 
3.66B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 53.73 
20-SMA 53.44 
50-SMA 54.65 
52-W High 68.58 
52-W Low 35.17 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.34/-1.49
Enterprise Value
3.66B
Balance Sheet
Book Value Per Share
0.34
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
130.13M
Operating Revenue Per Share
0.69
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.76+1.25+27.72%-- 
THTXTheratechnologies1.94+0.61+45.86%-- 
CDTConduit Pharmaceuticals Inc0.9101-0.1599-14.94%-- 
PRTGPortage Biotech Inc8.59+3.49+68.43%0.17PE
HEPAHepion Pharmaceuticals0.422-0.0091-2.11%-- 
Quotes are at least 15-min delayed:2025/04/13 01:46 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.